Fennec Pharmaceuticals Inc (NASDAQ: FENC) has reported E.P.S. of $-0.07 for its third fiscal quarter (ending September 30) versus $-0.31 for the same period a year ago. Relative to the consensus estimate of $-0.12, this was a premium of $0.05. For the latest four quarters through September 30, E.P.S. were $-0.76 versus $-0.83 for the same period a year ago.
Recent Price Action
On 11/6/23, Fennec Pharmaceuticals Inc (NASDAQ: FENC) stock enjoyed a major increase of 15.4%, closing at $7.96. Relative to the market the stock has been weak over the last nine months but has risen 16.4% during the last week.
Current PriceTarget Research Rating
FENC’s future returns on capital are forecasted to be below the cost of capital. Accordingly, the company is expected to be a major Value Eraser.
Fennec Pharmaceuticals is currently unrated.
Rating Review
The stock is currently unrated.
Be the first to comment